Results 331 to 340 of about 432,090 (383)

Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review

open access: hybrid
Saifur Rahman Chowdhury   +45 more
openalex   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Anticoagulant therapy in patients with cancer and thrombocytopenia. [PDF]

open access: yesJ Thromb Thrombolysis
Szmit S   +5 more
europepmc   +1 more source

Unstable Recompensation: An Intermediate Subtype in Patients With HBV‐Related Decompensated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Recompensation is a heterogeneous and dynamic state in HBV‐related decompensated cirrhosis; The prognosis for patients with unstable recompensation was found to be worse compared to those with stable recompensation, but still better than patients without recompensation; Subclassification of recompensation has significant implications for prognosis and ...
Shuai Xia   +19 more
wiley   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

open access: yesBritish Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan   +2 more
wiley   +1 more source

Protocol-Evaluation of Platelet Indices and serum LDH in Immune Thrombocytopenia: Diagnostic Utility of serum LDH

open access: gold
Karanth, Shubhada   +4 more
openalex   +1 more source

Home - About - Disclaimer - Privacy